{"id":3936,"date":"2018-02-26T16:48:40","date_gmt":"2018-02-26T21:48:40","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=3936"},"modified":"2018-02-26T16:48:40","modified_gmt":"2018-02-26T21:48:40","slug":"secondaries-announced-2-26-18","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/secondaries-announced-2-26-18\/","title":{"rendered":"Secondaries Announced 2.26.18"},"content":{"rendered":"<h4><strong>IPO BOUTIQUE CLIENTS\u00a0and\u00a0IPO BOUTIQUE SECONDARY ALERTS CLIENTS\u00a0received ALL this information to their inbox on a\u00a0REAL TIME\u00a0basis.<\/strong><\/h4>\n<p>If having\u00a0<a href=\"http:\/\/www.ipoboutique.com\/blog\/ipo-boutique-announces-new-secondary-alert-service\/#sthash.HnSepMmy.dpbs\" target=\"_blank\"><strong>real-time alerts for secondary offerings<\/strong><\/a>\u00a0would be an advantage to you,<a style=\"border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: #333333; color: #333333; text-decoration: none;\" href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">\u00a0inquire about a subscription today!<\/a><\/p>\n<p>Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or opening trade) time period.<\/p>\n<p>Company: Bright Scholar Education Holdings Limited<br \/>\nSymbol: BEDU<br \/>\nPrice: Last Trade $20.15<br \/>\nTrade Date: 3\/1<br \/>\nShares: 10 million<br \/>\nUnderwriter(s): Deutsche Bank, Goldman Sachs (Asia)<br \/>\nDescription: They are the largest operator of international and bilingual K-12 schools in China in terms of student enrollment as of September 1, 2017, according to the Frost &amp; Sullivan report.<br \/>\nRating = <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><\/p>\n<p>Company: InspireMD, Inc.<br \/>\nSymbol: NSPR<br \/>\nPrice: Last Trade $3.86<br \/>\nTrade Date:\u00a0TBD<br \/>\nShares: 3.2 million<br \/>\nRe-Offer Range: <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><br \/>\nUnderwriter(s): H.C. Wainwright &amp; Co.<br \/>\nDescription: InspireMD seeks to utilize its proprietary MicroNet\u2122 technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.<br \/>\nRating = <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><\/p>\n<p>Company: Tyme Technologies, Inc.<br \/>\nSymbol: TYME<br \/>\nPrice: Last Trade $3.88<br \/>\nTrade Date: 3\/1<br \/>\nShares: 12 million<br \/>\nUnderwriter(s): Evercore Group, Stifel, Canaccord<br \/>\nDescription: Tyme Technologies, Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types while having a low toxicity profile.<br \/>\nRating =<strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><\/p>\n<p>Company: NMI Holdings, Inc.<br \/>\nSymbol: NMIH<br \/>\nPrice: Last Trade $21.70<br \/>\nTrade Date: 2\/28<br \/>\nShares: 3.7 million<br \/>\nUnderwriter(s): J.P. Morgan, Deutsche Bank Securities, RBC Capital Markets<br \/>\nCo-Manager(s): SunTrust Robinson Humphrey, Dowling &amp; Partners Securities, Keefe Bruyette &amp; Woods, Zelman Partners<br \/>\nDescription: They are the parent company of National Mortgage Insurance Corporation (National MI), a U.S.-based, private mortgage insurance company enabling low down payment borrowers to realize home ownership while protecting lenders and investors against losses related to a borrower&#8217;s default.<br \/>\nRating = <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><\/p>\n<p>Company: RA Pharmaceuticals &#8211; Block<br \/>\nSymbol: RARX<br \/>\nPrice: Last Trade $6.71<br \/>\nTrade Date: 2\/27<br \/>\nShares: 0.5 million<br \/>\nRe-Offer Range: <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><br \/>\nUnderwriter(s): Morgan Stanley<br \/>\nDescription: Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases.<br \/>\nRating = <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IPO BOUTIQUE CLIENTS\u00a0and\u00a0IPO BOUTIQUE SECONDARY ALERTS CLIENTS\u00a0received ALL this information to their inbox on a\u00a0REAL TIME\u00a0basis. If having\u00a0real-time alerts for secondary offerings\u00a0would be an advantage to you,\u00a0inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[35],"tags":[],"class_list":["post-3936","post","type-post","status-publish","format-standard","hentry","category-secondary-offerings"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=3936"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3936\/revisions"}],"predecessor-version":[{"id":3937,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3936\/revisions\/3937"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=3936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=3936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=3936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}